Here are the 10-K annual reports from Inhibrx Biosciences, Inc. (INBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBX filings page.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on engineered biologics for difficult cancers, built around proprietary single-domain antibody and multispecific platforms. Following a 2024 spin-off from its former parent after a Sanofi transaction, the company now centers on two lead programs, ozekibart (INBRX-109) and INBRX-106.
Ozekibart, a tetravalent DR5 agonist, showed encouraging activity in colorectal cancer, Ewing sarcoma, and chondrosarcoma, including positive results from the randomized ChonDRAgon trial, where it more than doubled median progression-free survival versus placebo in advanced chondrosarcoma. Inhibrx plans a biologics license application in early second quarter 2026.
INBRX-106, a hexavalent OX40 agonist, is being tested alone and with KEYTRUDA in multiple solid tumors. Early combination data in non-small cell lung cancer and head and neck cancer showed responses after prior checkpoint exposure, and a seamless Phase 2/3 trial in first-line head and neck cancer is underway. The company reports broad global patent coverage across its molecules and platforms.